Soft Tissue & Orthopedic Surgery
Below, please find links to all of the clinical trials involving soft tissue or orthopedic surgery. The studies include a multitude of information, including (but not limited to) the study’s purpose, benefits for participating, and financial incentive information. If you have any questions, please contact the individual outlined at the end of each trial summary.
Please visit the Surgery service webpage at the Veterinary Medical Teaching Hospital (VMTH) if you would like to learn more about the amazing things that our surgeons can do for you and your animal.
Title: Intraoperative Near-Infrared Fluorescent Imaging
Purpose of Study: Near-infrared fluorescent imaging utilizes light just out of the visual spectrum to generate additional imaging information in the treatment of a wide variety of diseases. The near infrared light is generated by a special contrast agent (Indocyanine Green) that is injected into the patient. When a near-infrared light source is used to illuminate the surgical site, any tissue in which this contrast agent is located will glow, aiding the surgeon in identifying the location or extent of disease. Based on early experiments in rodents and human clinical trials, this very sensitive tool has the potential to improve surgical decision-making and improve overall treatment for a wide variety of diseases including various tumors, sentinel lymph node identification, assessing viability of skin flaps, identification of liver shunts, identification of urinary tract obstruction or trauma, identification of bilary tract obstruction or trauma, assessment of gastrointestinal perfusion, and treatment of difficult wounds. The purpose of this study is to evaluate the efficacy of this imaging modality in veterinary patients presenting with natural disease processes.
Participation Requirements: Dogs scheduled for surgery.
Initial Evaluation for Participation: Evaluation by Dr. Michele Steffey on the Soft Tissue Surgery Service.
Procedures: Indocyanine Green will be administered, either subcutaneously or intravenously, at a dose and timing considered to be optimal by your attending veterinarian.
Benefits: There may or may not be a specific benefit to your dog by participating in this study. Use of Indocyanine Green may or may not aid in the intraoperative decision-making by the veterinary surgeon.
Owner Responsibilities: If an allergic reaction should occur, immediate costs of treatment (diphenhydramine, support of blood pressure) will be covered by the study; however, the owner will be responsible for any treatment costs for prolonged or severe complications.
Contact: Call the scheduling coordinators in Soft Tissue Surgery at (530) 752-1393 for Dr. Steffey's study.
Title: Assessment of Outcome in Dogs Undergoing Percutaneous Transvenous Coil Embolization to Treat Intrahepatic Portosystemic Shunts
Purpose of Study: The purposes of this project are to:
- Evaluate serum bile acid concentrations and hepatic biochemical functional parameters (BUN, albumin, cholesterol, glucose, and bilirubin) in dogs with intrahepatic portosystemic shunts both pre- and post-treatment to objectively evaluate each patient for improvement in hepatic function.
- Assess the improvement in the clinical signs of dogs with IHPSS after the performance of PTCE.
- To perform imaging studies pre- and post-PTCE that provide objective assessment of outcome associated with the PTCE procedure.
Participation Requirements: Dogs with intrahepatic portosystemic shunts
Initial Evaluation for Participation: Contact Dr. Culp for details at firstname.lastname@example.org or (530) 752-1393.
Procedures: Dogs with a diagnosis of intrahepatic portosystemic shunts (IHPSS) will be enrolled in the study. The dog will undergo percutanous transvenous coil embolization (PTCE) to treat his/her IHPSS. Prior to and after this procedure, diagnostics including bloodwork, nuclear scintigraphy, abdominal ultrasound and computed tomography (CT) scan will be performed and compared.
Benefits: Enrolling a dog in this study results in a significant financial incentive towards diagnostics that would be recommended for the dog whether or not he/she is enrolled in the study. This benefit includes payment of the preoperative CT scan and the postoperative bloodwork (1 chemistry panel at 3 months postoperative), ultrasound (1 at 3 months postoperative), nuclear scintigraphy scan (1 at 3 months postoperative) and CT scan (1 at 3 months postoperative).
Owner Responsibilities: Return the patient 3 months after treatment for further assessment.
Contact: Contact Dr. Culp for details at email@example.com or (530) 752-1393.
Title: Evaluation of CT pneumocolonography as a diagnostic tool in veterinary patients
Purpose of Study: The purpose of this study is to evaluate the impact of imaging findings on surgical decision-making in dogs with colonic and rectal disease of any kind (cancer or non-cancer). This part of the body can be a very difficult region examine with current imaging methods, which also do not provide optimal spatial information important if a surgical procedure is needed. In early studies, we have demonstrated the safety and efficacy of the CT pneumocolonography procedure in normal dogs, but it is important that we learn to accurately interpret the imaging findings for a wide variety of disease processes in clinical patients so that our CT diagnoses are accurate. Our goal is to compare the imaging findings obtained with CT pneumocolonography with the current standard of care of colonoscopy and colonoscopic biopsies.
Participation Requirements: In order to participate in this study, a colonoscopic exam must have been recommended for workup of your dog’s problem, and your dog must be scheduled to receive a colonoscopic exam under general anesthesia at UC Davis.
Initial Evaluation for Participation: None.
Procedures: If you agree to participate, your dog will receive a CT scan (with and without intravenous contrast material) in conjunction with carbon dioxide gas insufflated into the rectal lumen. Following CT pneumocolonography, your dog will receive the scheduled colonoscopy, which is the current standard of care for assessment of these masses, and if clinically indicated for the care of your dog, biopsies will be obtained.
Benefits: In return for participation in this study, your dog will receive a free CT scan (an approximately $800 value to you), which may directly benefit your dog, as it can provide important information for treatment recommendations that other types of imaging cannot. CT evaluation of local lymph nodes is an additional benefit as CT has been demonstrated to be helpful in the evaluation of regional lymph nodes for metastatic disease in other types of cancer in other locations.
Owner Responsibilities: There is no additional cost to you for your dog’s participation in the study. You are financially responsible for hospital costs associated with the standard care of your dog, including abdominal ultrasound, general anesthesia, colonoscopy, hospitalization, biopsies, and any other diagnostic tests recommended for evaluation of your dog’s disease by your attending clinician.
Contact: Call 530-752-1393 for Drs. Michele Steffey and Stanley Marks's study